HITIQ Ltd (ASX:HIQ) Announces Partnership with AFL Barwon to Expand PROTEQT
A three-year partnership with AFL Barwon aims to expand HITIQ’s PROTEQT concussion management technology to over 25,000 players in regional Victoria.
Tag: Corporate Strategy & Guidance
Goodman Group (ASX:GMG) Releases Q3 FY25 Operational Update
Goodman Group (ASX:GMG) reports Q3 FY25 operational progress with $13.7bn WIP and reaffirms 9% EPS growth forecast.
Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans
Neuren Pharmaceuticals (ASX:NEU) reports a record A$166m income in 2024, driven by DAYBUE sales and initiates Phase 3 trials for NNZ-2591.
Imugene Limited (ASX:IMU) Announces Extraordinary General Meeting
Imugene Limited (ASX:IMU) announces an Extraordinary General Meeting to discuss share consolidation and the issuance of new shares to support its clinical projects.
Assetora Limited (ASX:AOH) Announces Launch of Australian Homeowner Equity Fund
Assetora Limited (ASX:AOH) launches the Australian Homeowner Equity Fund, providing a unique shared equity solution for investors and homeowners.
DXN Limited (ASX:DXN) Secures A$2m Data Centre Contract with DP World Australia
DXN Limited (ASX:DXN) secures a A$2 million contract with DP World Australia to deliver modular data centres in New South Wales.
American West Metals Limited (ASX:AW1) Secures A$5.9M Equity Raising
American West Metals (ASX:AW1) successfully raises A$5.9M through equity placement to advance its Storm Copper Project.
Beacon Minerals Limited (ASX:BCN) Executes Wealth of Nations Option Agreement
Beacon Minerals Limited (ASX:BCN) acquires option for Wealth of Nations tenements, initiating a drilling program near its Jaurdi plant.
Horseshoe Metals Ltd (ASX:HOR) Recommissions Infrastructure at Horseshoe Lights
Horseshoe Metals Ltd (ASX:HOR) recommissions infrastructure at Horseshoe Lights to support DSO operations and Melody Gold’s processing activities.
OncoSil Medical Limited (ASX:OSL) Announces $8.7M Capital Raise to Drive Commercialisation
OncoSil Medical (ASX:OSL) secures $8.7 million in capital to advance commercialisation and support ongoing clinical trials.